Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis and hematological malignancies.

Soon Thye Lim1, Alexandra M Levine

  • 1Keck School of Medicine/Norris, university of Southern california, Comprehensive Cancer center, Los Angeles, CA 90033, USA.

Hematology (Amsterdam, Netherlands)
|July 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma.

BMC medicine·2026
Same author

Real-World Insights Into the Clinical Characteristics and Survival Outcomes of Extranodal Peripheral T-Cell Lymphomas: A Multiethnic Asian Cohort Study.

EJHaem·2025
Same author

Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

JCO global oncology·2025
Same author

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

JCO global oncology·2025
Same author

Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma.

Cancer discovery·2025
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Angiogenesis, the formation of new blood vessels, is crucial in cancer. Vascular endothelial growth factor (VEGF) drives this process, offering a target for anti-angiogenic therapies in hematological malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Angiogenesis, or new blood vessel formation, plays a critical role in cancer development.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, influencing cell proliferation, survival, migration, and adhesion.
  • Understanding these mechanisms is vital for developing novel cancer treatments.

Purpose of the Study:

  • To review the role of angiogenesis and its mediators, particularly VEGF, in hematological malignancies.
  • To explore the potential of anti-angiogenic therapies for managing these blood cancers.

Main Methods:

  • Literature review focusing on angiogenesis and VEGF in cancer pathogenesis.
  • Analysis of current research on anti-angiogenic strategies in hematological malignancies.

Related Experiment Videos

Main Results:

  • VEGF is a significant factor in the pathogenesis of hematological malignancies.
  • Inhibition of the VEGF signaling pathway presents a promising therapeutic target.

Conclusions:

  • Targeting angiogenesis, specifically VEGF, holds significant therapeutic potential for hematological cancers.
  • Anti-angiogenic therapies represent a developing frontier in the management of blood-related cancers.